However, while itolizumab activates cytotoxic lymphocytes challenged with MCF-7, it does not enhance cytotoxic capacity against these CD318 cell lines, reinforcing the theory that the increased tumor cell killing by itolizumab depends on the blockade of the CD6-CD318 interaction. The gene discussed is CDCP1; the disease is neoplasm.